No federal rescheduling of any classical psychedelic — psilocybin, MDMA, LSD, DMT — will occur before 2028.

The federal government won't move psilocybin, MDMA, LSD, or DMT from Schedule I (the strictest category) to a lower schedule before 2028. This matters because rescheduling is the only legal path that lets doctors prescribe these drugs widely — and it requires the FDA to first approve one as a medicine, which hasn't happened yet.

No classical psychedelic has an FDA-approved NDA, which is the statutory prerequisite for DEA rescheduling that would survive legal challenge. Congressional standalone rescheduling bills lack floor votes and leadership support in the 119th Congress. The pathway does not exist within the timeframe.